Could a designer probiotic tame IBD Flare-Ups?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Patients with ulcerative colitis (UC) Patients diagnosed with UC according to the 'Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023, Xi'an)'. 1. Patients with non-infectious UC initially diagnosed through laboratory tests, endoscopy, and pathological biopsy; 2. According to the latest guideline standards, clinically diagnosed with mild to moderate disease; defined as a modified Mayo score of 3-9 points; and classified as mild to moderate based on the modified Truelove and Witts severity classification; 3. In the active phase, with a clinical treatment plan using only mesalazine; 4. Voluntarily participating in this clinical trial, understanding, and signing the informed consent form. 2\. Patients with Crohn's disease (CD) Patients diagnosed with Crohn's disease (CD) according to the 'Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (2023, Guangzhou)'. 1. Patients with non-infectious Crohn's disease (CD) initially diagnosed through laboratory tests, endoscopic examination, and pathological biopsy; 2. Clinically diagnosed as having mild to moderate disease according to the latest guideline standards, defined as a Crohn's Disease Activity Index (BestCDAI) score of 150-450; 3. Voluntarily participating in this clinical trial, having understood and signed the informed consent form. Exclusion Criteria: 1\. Patients with ulcerative colitis (UC) Patients diagnosed with UC according to the 'Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023, Xi'an)'. 1. Patients who have changed medication dosage or type in the past 2 months; 2. Patients who have the history of antibiotics, probiotics, or other medications affecting gut microbiota for non-target diseases within the past 2 months; 3. Patients who have the history of immunosuppressive drugs such as methotrexate or glucocorticoids ; 4. Patients who have the history of malignant tumors, other immune system diseases, or other serious chronic diseases; 5. Patients who have Concurrent active infections, including but not limited to obvious gastrointestinal bleeding, local or systemic infectious symptoms due to severe gastrointestinal ulceration or bleeding; 6. Pregnant or preparing for pregnancy and breastfeeding women; 7. Other situations deemed necessary to exclude by the researcher, for example: Simultaneous participation in other clinical interventional studies that may interact with this study. 2\. Patients with Crohn's disease (CD) Patients diagnosed with Crohn's disease (CD) according to the 'Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (2023, Guangzhou)'. 1. Patients who have changed medication dosage or type in the past 2 months; 2. Patients who have the history of antibiotics, probiotics, or other medications affecting gut microbiota for non-target diseases within the past 2 months; 3. Patients who have the history of malignant tumors, other immune system diseases, or other serious chronic diseases; 4. Patients who have Concurrent active infections, including but not limited to obvious gastrointestinal bleeding, local or systemic infectious symptoms due to severe gastrointestinal ulceration or bleeding; 5. Pregnant or preparing for pregnancy and breastfeeding women; 6. Other situations deemed necessary to exclude by the researcher, for example: Simultaneous participation in other clinical interventional studies that may interact with this study.